Company search
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Engage
Unlisted holdings
Data as at : 01/12/2023
| % of total assets |
|---|
| 6.3 |
Please note that the percentage of unlisted holdings is displayed for companies that have reported this data to the AIC. “N/R” means the data has not been reported to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 31/12/2023
| Investment | % of total assets |
|---|---|
| Eli Lilly and Co | 7.3 |
| Novo Nordisk A/S Class B | 6.3 |
| AstraZeneca PLC | 6.0 |
| Boston Scientific Corp | 6.0 |
| Intuitive Surgical Inc | 5.3 |
| Biogen Inc | 4.9 |
| Merck & Co Inc | 3.8 |
| Biomarin Pharmaceutical Inc | 3.7 |
| Daiichi Sankyo Co Ltd | 3.4 |
| Other Assets And Liabilities | -3.0 |
Geographic breakdown
Data as at : 31/03/2024
| Country | % of total assets |
|---|---|
| USA | 69.0 |
| UK | 8.7 |
| Denmark | 6.3 |
| Japan | 6.3 |
| China | 5.8 |
| Ireland | 1.8 |
| Netherlands | 1.5 |
| Hong Kong | 0.6 |
| Switzerland | 0.6 |
| India | 0.3 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 31/03/2024
| Industry | % of total assets |
|---|---|
| Healthcare | 94.4 |
| Preferred | 5.8 |
| Cash Equivalents | 3.5 |
| Consumer Defensive | 0.6 |
Scroll
Asset breakdown
Data as at : 31/03/2024
| Asset | % of total assets |
|---|---|
| Stock | 100.8 |
| Other | -4.3 |
| Cash/Cash equivalents | 3.5 |
Detailed asset breakdown
Data as at : 31/03/2024
| Asset | % of total assets |
|---|---|
| North America - stock | 70.1 |
| Europe - Large-cap stock | 6.3 |
| Japan - stock | 6.2 |
| UK - Large growth stock | 6.2 |
| Preferred stock | 5.8 |
| Cash | 3.5 |
| Asia (excl Japan) - stock | 3.0 |
| UK - Large core/value stock | 2.4 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
